Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT05153434
PHASE2
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
Sponsor: Aardvark Therapeutics, Inc.
View on ClinicalTrials.gov
Summary
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
Official title: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome (PWS)
Key Details
Gender
All
Age Range
17 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
19
Start Date
2022-05-27
Completion Date
2024-09-24
Last Updated
2026-09-08
Healthy Volunteers
No
Conditions
Interventions
DRUG
ARD-101
Oral administration of ARD-101 taken BID (twice daily) for 28 days.
Locations (2)
Stanford University
Palo Alto, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States